<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977194</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1805</org_study_id>
    <nct_id>NCT03977194</nct_id>
  </id_info>
  <brief_title>Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy</brief_title>
  <acronym>ELDERLY</acronym>
  <official_title>Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world.&#xD;
      Because of the increase in lung cancer incidence with age and the increase of life&#xD;
      expectancy, about half of the patients are patients aged 70 or older. Several clinical trials&#xD;
      have shown the interest of adding immunotherapy to standard 1st line chemotherapy in NSCLC.&#xD;
      Although in these studies there was not necessarily a higher age limit, in fact the&#xD;
      proportion of included patients aged 75 or older remains low (between 7 and 10%). It is&#xD;
      therefore necessary to conduct a trial dedicated to these patients in order to determine&#xD;
      whether immunotherapy is as effective and tolerated as in the general population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>11 months after randomization of the last subject</time_frame>
    <description>Time from randomization until death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>11 months after randomization of the last subject</time_frame>
    <description>Time from randomization to first observation of progression (according to RECIST v1.1) or date of death (from any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>11 months after randomization of the last subject</time_frame>
    <description>Best response according to RECIST v1.1 from start to end of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>11 months after randomization of the last subject</time_frame>
    <description>Time from documentation of tumor response to disease progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatine + paclitaxel (4 cycles of 28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : standard treatment + immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatine + paclitaxel (4 cycles of 28 days) + atezolizumab (every 21 days) until progression or toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 6 every 4 weeks</description>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_label>Arm B : standard treatment + immunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>90 mg/m² D1, 8, 15, every 4 weeks</description>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_label>Arm B : standard treatment + immunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg every 3 weeks</description>
    <arm_group_label>Arm B : standard treatment + immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Written Informed Consent:&#xD;
&#xD;
               -  Subjects must have signed and dated an IRB/IEC approved written informed consent&#xD;
                  form in accordance with regulatory and institutional guidelines. This must be&#xD;
                  obtained before the performance of any protocol related procedures that are not&#xD;
                  part of normal subject care.&#xD;
&#xD;
               -  Subjects must be willing and able to comply with scheduled visits, treatment&#xD;
                  schedule, and laboratory testing&#xD;
&#xD;
          2. Histologically confirmed NSCLC. A cytologically-proven NSCLC is allowed if a cytoblock&#xD;
             has been prepared.&#xD;
&#xD;
          3. Age: 70 to 89 years&#xD;
&#xD;
          4. Performance status ≤1.&#xD;
&#xD;
          5. Stage IIIB or IIIC non irradiable or IV (8th classification TNM, UICC 2015)&#xD;
&#xD;
          6. Measurable disease as defined by RECIST 1.1&#xD;
&#xD;
          7. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as&#xD;
             primary therapy for advanced or metastatic disease. Previously irradiated lesion must&#xD;
             not be the only measurable site of disease.&#xD;
&#xD;
          8. At least 3 weeks must have elapsed after major surgery or radiation therapy&#xD;
&#xD;
          9. Adequate biological functions:&#xD;
&#xD;
             Creatinine Clearance ≥ 45 mL/min (Cockcroft or MDRD or CKD-epi); neutrophiles ≥&#xD;
             1500/mm3 ; platelets ≥100 000/mm3 ; Hemoglobin ≥ 9g/dL ; hepatic enzymes &lt; 3x ULN&#xD;
             except for patients with hepatic metastases (&lt; 5 x ULN), total bilirubin ≤ 1,5 x ULN&#xD;
             except for patients with proved, Gilbert syndrome (≤ 5 x ULN) or patients with hepatic&#xD;
             metastases (≤ 3,0 mg/dL).&#xD;
&#xD;
         10. Life expectancy of at least 12 weeks&#xD;
&#xD;
         11. For male patients with female partners of childbearing potential, agreement (by&#xD;
             patient and/or partner) to use a highly effective form(s) of contraception that&#xD;
             results in a low failure rate [&lt; 1% per year] when used consistently and correctly,&#xD;
             and to continue its use for 6 months after the last dose of treatment. Male patients&#xD;
             should not donate sperm during this study and for at least 6 months after the last&#xD;
             dose of treatment.&#xD;
&#xD;
             Oral contraception should always be combined with an additional contraceptive method&#xD;
             because of a potential interaction with the treatment. Male patients must always use a&#xD;
             condom.&#xD;
&#xD;
         12. Patient covered by a national health insurance&#xD;
&#xD;
         13. Protected adults can participate if they are able to make decision about their medical&#xD;
             treatment according to guardianship judgment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Small cell lung cancer or tumors with mixt histology including a SCLC component&#xD;
&#xD;
          2. Known EGFR activating tumor mutation.&#xD;
&#xD;
          3. Known ALK or ROS1 gene rearrangement as assessed by IH, FISH or NGS sequencing&#xD;
&#xD;
          4. Previous or active cancer within the previous 3 years with the exception of those with&#xD;
             a negligible risk of metastasis or death and treated with expected curative outcome&#xD;
             (such as adequately treated carcinoma in situ of the cervix, basal cell skin cancer or&#xD;
             ductal carcinoma in situ treated surgically with curative intent. For other type of&#xD;
             cancer, please contact IFCT). Patients with a prostate adenocarcinoma history within&#xD;
             the previous 3 years could be included in case of localized prostate cancer, with good&#xD;
             prognostic factors according to d'Amico classification (≤ T2a and Score de Gleason ≤ 6&#xD;
             and PSA (ng/ml) ≤ 10), provided they were treated in a curative way (surgery or&#xD;
             radiotherapy ± hormonotherapy, without any chemotherapy)&#xD;
&#xD;
          5. Mini Mental Score &lt; 24&#xD;
&#xD;
          6. Previous systemic treatment (including but not limited to chemotherapy, targeted&#xD;
             treatment or immunotherapy) except for adjuvant therapy given more than 5 years ago.&#xD;
&#xD;
          7. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
          8. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or any component of the atezolizumab formulation&#xD;
&#xD;
          9. History of autoimmune disease, including but not limited to myasthenia gravis,&#xD;
             myositis, autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel&#xD;
             disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's&#xD;
             granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis,&#xD;
             vasculitis, or glomerulonephritis Patients with a history of autoimmune-related&#xD;
             hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this&#xD;
             study.&#xD;
&#xD;
             Patients with rheumatoid arthritis without exacerbation during one year and with no&#xD;
             more than 10 mg oral prednisone /day or equivalent may be included after&#xD;
             rheumatologist advice.&#xD;
&#xD;
             Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen&#xD;
             are eligible for this study&#xD;
&#xD;
             Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
             dermatologic manifestations only (e.g., patients with psoriatic arthritis would be&#xD;
             excluded) are permitted provided that they meet the following conditions:&#xD;
&#xD;
               -  Rash must cover less than 10% of body surface area (BSA).&#xD;
&#xD;
               -  Disease is well controlled at baseline and only requiring low potency topical&#xD;
                  steroids.&#xD;
&#xD;
               -  No acute exacerbations of underlying condition within the previous 12 months (not&#xD;
                  requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids,&#xD;
                  biologic agents, oral calcineurin inhibitors, high potency or oral steroids)&#xD;
&#xD;
         10. Symptomatic brain metastases requiring corticosteroids.&#xD;
&#xD;
         11. Spinal cord compression not definitely treated by surgery and/or radiation therapy or&#xD;
             with neurological sequelae.&#xD;
&#xD;
         12. Leptomeningeal disease&#xD;
&#xD;
         13. Uncontrolled tumor-related pain.&#xD;
&#xD;
         14. Uncontrolled or symptomatic or requiring Denosumab hypercalcemia .&#xD;
&#xD;
         15. Corticosteroids &gt; 10mg oral prednisone/day or equivalent.&#xD;
&#xD;
         16. Immunosuppressive medications within 2 weeks before randomization&#xD;
&#xD;
         17. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is&#xD;
             permitted.&#xD;
&#xD;
         18. HIV positive serology (test at screening),&#xD;
&#xD;
         19. Patients with active hepatitis B (chronic or acute; defined as having a positive&#xD;
             hepatitis B surface antigen HBsAg test at screening) or hepatitis C Patients with past&#xD;
             hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence&#xD;
             of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible only if they&#xD;
             are negative for HBV DNA.&#xD;
&#xD;
             Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is&#xD;
             negative for HCV RNA.&#xD;
&#xD;
         20. Active tuberculosis&#xD;
&#xD;
         21. Severe infection within 4 weeks before randomization&#xD;
&#xD;
         22. Received therapeutic oral or iv antibiotics within 2 weeks before randomization.&#xD;
&#xD;
         23. Administration of live attenuated vaccine within four weeks before randomization or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study.&#xD;
&#xD;
         24. Serious undergoing diseases or comorbidities precluding the possibility for the&#xD;
             patient to receive the treatments.&#xD;
&#xD;
         25. Polyneuropathy ≥ grade 2 CTC&#xD;
&#xD;
         26. Treatment with an investigational drug during the 4 weeks preceding inclusion in the&#xD;
             trial.&#xD;
&#xD;
         27. Known allergy to Cremophor EL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth QUOIX</last_name>
    <role>Study Chair</role>
    <affiliation>Strasbourg - NHC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Céline MASCAUX</last_name>
    <role>Study Chair</role>
    <affiliation>Strasbourg - NHC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbeville - CH</name>
      <address>
        <city>Abbeville</city>
        <zip>80142</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier LELEU, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aix-en-Provence - CH</name>
      <address>
        <city>Aix-en-Provence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie MARTINEZ, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annemasse - CH</name>
      <address>
        <city>Ambilly</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidia PETIT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metz - Thionville CHR</name>
      <address>
        <city>Ars-Laquenexy</city>
        <zip>57530</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand MICHY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auxerre - CH</name>
      <address>
        <city>Auxerre</city>
        <zip>89011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adina MARTI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avignon - Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alma STANCU, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avignon - CH</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas CLOAREC, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bayonne - CH</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie SCHNEIDER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Besançon - CHU</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie WESTEEL</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bobigny - APHP - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris DUCHEMANN, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - CHU Hôpital Haut-Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte DOMBLIDES, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Polyclinique Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigolène GALLAND-GIRODET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Sigolène GALLAND GIRODET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boulogne - Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen - Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Radj GERVAIS, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannick MADELAINE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cannes - CH</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick DUVAL</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carcassone - CH</name>
      <address>
        <city>Carcassonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc LABOUREY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne BARANZELLI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chauny - Centre Hospitalier</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick DUMONT, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cholet - CH</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MASSON, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clamart - Hôpital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé LE FLOCH, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand - CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaelle JEANNIN, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colmar - CH</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel MOREAU, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornebarrieu - Clinique des Cèdres</name>
      <address>
        <city>Cornebarrieu</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iona CARPIUC, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon - Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coureche-Guillaume KADERBHAI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble - CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis MORO-SIBILOT, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Le Mans - CHG</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MOLINIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille - GHICL</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille MUNCK, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille - Polyclinique de la Louvière</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin HURET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin HURET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limoges - CHU</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas EGENOD, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lorient - CHBS</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud PEDRONO, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon - Hôpital Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima BOULEDRAK, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille - AP-HM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GREILLIER</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille - Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille - Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne MADROSZYK, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meaux - CH</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrystèle Locher, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mont de Marsan - CH</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela PETRAN, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montauban - CH</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah ZAHI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier des Pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim AMRANE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mulhouse - GHRMSA</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy - Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle CLEMENT-DUCHENE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes - CHU Hôpital Laënnec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvire PONS-TOSTIVINT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nice - CRLCC</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josiane OTTO, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orléans - CH</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion CAMPANA, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Hôpital Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane JOUVESHOMME, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - APHP - Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle LAVOLE, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - APHP Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Gounant, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie Gounant, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris - Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Ange MASSIANI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie WISLEZ, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pau - CHG</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo RENAULT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon - URCOT</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien COURAUD, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quint-Fonsegrives - Clinique de la Croix du Sud</name>
      <address>
        <city>Quint-Fonsegrives</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Pascale LAURENTY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rodez - CH</name>
      <address>
        <city>Rodez</city>
        <zip>12021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique FABRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Cloud - Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Ange MASSIANI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Réunion - CHU (site Félix GUYON)</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel ANDRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Mémorial de Saint-Lô</name>
      <address>
        <city>Saint-Lô</city>
        <zip>50000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud VILLEMIN, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint- Mandé - HIA Begin</name>
      <address>
        <city>Saint-Mandé</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole HELISSEY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Réunion - CHU (Site Sud)</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric HUCHOT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Priest - Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-priest En Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Fournel, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Fournel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne - CHU</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie BAYLE-BLEUEZ, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sens - CH</name>
      <address>
        <city>Sens</city>
        <zip>89100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure CHAUVENET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg - Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline MASCAUX, Pr</last_name>
      <phone>0156811046</phone>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suresnes - Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine FRABOULET-MOREAU, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulon - CHI</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarisse Audigier-Valette, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulon - HIA</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BYLICKI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse - CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence BIGAY-GAME, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tours - CHU</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Pichon, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valence - CH</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie PAULUS-JACQUEMET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valenciennes - Clinique</name>
      <address>
        <city>Valenciennes</city>
        <zip>59304</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géraldine LAURIDANT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Villefranche-Sur-Saône - Hôpital Nord-Ouest</name>
      <address>
        <city>Villefranche-Sur-Saône</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc ODIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ifct.fr/index.php/fr/la-recherche/item/2149-ifct-1805-elderly</url>
    <description>IFCT website</description>
  </link>
  <reference>
    <citation>Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8.</citation>
    <PMID>21831418</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IFCT</keyword>
  <keyword>ELDERLY</keyword>
  <keyword>NSCLC</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

